OncoMatch/Clinical Trials/NCT05172310
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Is NCT05172310 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including PET/CT and 68Ga-FAPI-46 for pancreatic neoplasms.
Treatment: PET/CT · 68Ga-FAPI-46 — Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis. These cancers can be difficult to diagnose and sometimes impossible to differentiate from underlying benign conditions. Establishing the correct diagnosis of primary cancer lesions and possible spread to other organs in time is pivotal for choosing the right therapy. Routinely applied staging procedures are however not always reliable. The main aim in this study is to evaluate the diagnostic accuracy of PET/CT with a novel radiotracer, FAPI, in the primary diagnosis of cancers in the pancreas, stomach and bile ducts as well as in patients with primary and recurrent epithelial ovarian cancer (EOC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Gastric Cancer
Ovarian Cancer
Disease stage
Excluded: Stage IV
Known metastatic disease [excluded for pancreatic, gastric, or bile duct cancer]; early stage EOC; recurrent EOC
Lab requirements
Kidney function
Significantly reduced renal function [excluded]
Significantly reduced renal function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify